Archimedes wins US approval of Lazanda as first fentanyl nasal spray
This article was originally published in Scrip
Executive Summary
The US FDA on 30 June approved Archimedes Pharma's Lazanda as the first and only fentanyl nasal spray for the US market indicated to manage breakthrough pain in cancer patients 18 years or older already receiving and tolerant to opioid therapy for their underlying persistent pain.